Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NQ301 是一种抗血栓剂,能够抑制胶原蛋白激发的兔血小板聚集,IC50=10 mg/mL。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 225 | 现货 | ||
5 mg | ¥ 498 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,250 | 现货 | ||
50 mg | ¥ 1,930 | 现货 | ||
100 mg | ¥ 2,880 | 现货 | ||
500 mg | ¥ 6,580 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 548 | 现货 |
产品描述 | NQ301, an antithrombotic agent, inhibits collagen-challenged rabbit platelet aggregation (IC50: 10 mg/mL). |
靶点活性 | Platelet aggregation (rabbit, collagen-challenged):10 mg/mL |
体外活性 | NQ301 dose-dependently inhibits collagen (10 mg/mL, IC50: 0.60±0.02 μM), U46619 (1 mg/mL, IC50: 0.58±0.04 μM) and arachidonic acid (100 mg/mL, IC50: 0.78±0.04 μM) challenged rabbit platelet aggregation. NQ301 potently suppresses thromboxane B2 formation by platelets that are exposed to arachidonic acid in a concentration-dependent manner, but had no effect on the production of prostaglandin D2, indicating an inhibitory effect on thromboxane A2 synthase. NQ301 markedly inhibits the increase of cytosolic Ca2+ concentration and ATP secretion, and also markedly increases platelet cAMP levels in the activated platelets. The antiplatelet activity of NQ301 may be mediated by inhibition of cytosolic Ca2+ mobilization, enhancement of cAMP production and inhibition of ATP secretion in activated platelets. |
激酶实验 | Compounds are dissolved in DMSO (5 mg/mL) and diluted with PBS/EtOH (70:30).Kinetic analyses are carried out for TB5 and TB8. A set of Lineweaver–Burk plots are constructed in the absence and presence of various concentrations of compounds TB5 and TC8. The set consists of five graphs, each constructed by measuring MAO-B and MAO-A catalytic rates at different substrate concentrations (0.1-1 μM). The first Lineweaver–Burk plot is constructed in the absence of inhibitor, while the remaining four graphs are constructed in the presence of different concentrations of TB5 and TB8[1]. |
细胞实验 | ished rabbit platelet suspension is challenged by addition of collagen (10 mg/mL), arachidonic acid (100 μM) or U46619 (1 μM). Concentration- response relationship is determined in the absence or presence of a range of concentrations of NQ301 (0, 0.25, 0.5, 0.75, 1 μM); aspirin-treated platelets (50 μM for 5 min) are used to prevent any possible contribution of endogenous arachidonic acid metabolites to platelet aggregation. The resulting aggregation, measured as the change in light transmission, is recorded for 5 min. The extent of platelet aggregation is expressed as % of the control[1]. |
分子量 | 325.75 |
分子式 | C18H12ClNO3 |
CAS No. | 130089-98-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 29 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NQ301 130089-98-4 Others Proteases/Proteasome Thrombin Platelet aggregation inhibit Inhibitor NQ 301 NQ-301 inhibitor